Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRD-lite in relapsed/refractory multiple myeloma
ChiCTR1900026349Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: progression-free survival. Started Oct 2019; status: recruiting.
02
Drugs
ixazomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR1900026349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026349.